1119 SynOx series A
BioCentury & Getty Images

Finance

VCs back Celleron spinout with €37M to develop former Roche asset for rare joint disorder

Nov 19, 2020 | 8:27 PM GMT

A European VC syndicate shared Celleron’s belief that a single-asset start-up was the best place to develop emactuzumab, an

Read the full 471 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE